Q3 Earnings Estimate for MDGL Issued By Leerink Partnrs

Key Points

• Leerink Partners has significantly lowered its earnings per share (EPS) estimate for Madrigal Pharmaceuticals' Q3 2025, projecting a loss of ($6.37), a decrease from a previous forecast of ($1.61).
• Despite the negative forecast, Madrigal Pharmaceuticals reported a significant revenue increase of 1357.5% year-over-year, with $212.80 million for the last quarter, exceeding expectations of $158.94 million.
• Market analysts are bullish on Madrigal, with multiple firms assigning buy ratings and a consensus average price target of $421.63 despite recent earnings pressure.

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) - Investment analysts at Leerink Partnrs reduced their Q3 2025 earnings per share estimates for shares of Madrigal Pharmaceuticals in a research note issued on Tuesday, August 5th. Leerink Partnrs analyst T. Smith now anticipates that the biopharmaceutical company will post earnings per share of ($6.37) for the quarter, down from their previous estimate of ($1.61). The consensus estimate for Madrigal Pharmaceuticals' current full-year earnings is ($23.47) per share. Leerink Partnrs also issued estimates for Madrigal Pharmaceuticals' Q4 2025 earnings at $0.48 EPS, FY2025 earnings at ($10.92) EPS, FY2026 earnings at $4.58 EPS and FY2027 earnings at $17.41 EPS.

Other research analysts have also recently issued research reports about the company. Wall Street Zen upgraded Madrigal Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Monday, May 5th. JMP Securities restated a "market outperform" rating and issued a $443.00 target price on shares of Madrigal Pharmaceuticals in a research note on Thursday, April 24th. B. Riley reiterated a "buy" rating and set a $460.00 price objective (up previously from $422.00) on shares of Madrigal Pharmaceuticals in a research note on Friday, May 2nd. Canaccord Genuity Group lifted their price objective on Madrigal Pharmaceuticals from $420.00 to $428.00 and gave the company a "buy" rating in a research note on Wednesday, August 6th. Finally, UBS Group reiterated a "buy" rating and set a $523.00 price objective (up previously from $458.00) on shares of Madrigal Pharmaceuticals in a research note on Tuesday. Two research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $439.71.

Madrigal Pharmaceuticals Stock Up 2.5%

Shares of MDGL traded up $8.58 on Friday, reaching $358.08. The stock had a trading volume of 359,213 shares, compared to its average volume of 375,339. The firm has a market capitalization of $7.95 billion, a price-to-earnings ratio of -27.90 and a beta of -1.02. The company has a debt-to-equity ratio of 0.17, a quick ratio of 4.78 and a current ratio of 5.11. The company has a 50-day simple moving average of $303.20 and a 200-day simple moving average of $312.98. Madrigal Pharmaceuticals has a 12-month low of $200.63 and a 12-month high of $377.46.

Madrigal Pharmaceuticals (NASDAQ:MDGL - Get Free Report) last released its earnings results on Tuesday, August 5th. The biopharmaceutical company reported ($1.90) EPS for the quarter, beating analysts' consensus estimates of ($3.48) by $1.58. The company had revenue of $212.80 million during the quarter, compared to analysts' expectations of $158.94 million. Madrigal Pharmaceuticals had a negative return on equity of 38.38% and a negative net margin of 54.68%. The firm's revenue for the quarter was up 1357.5% compared to the same quarter last year. During the same quarter last year, the business posted ($7.10) EPS.

Institutional Trading of Madrigal Pharmaceuticals

Several large investors have recently modified their holdings of the company. Mutual of America Capital Management LLC lifted its position in Madrigal Pharmaceuticals by 0.3% during the first quarter. Mutual of America Capital Management LLC now owns 11,263 shares of the biopharmaceutical company's stock valued at $3,731,000 after purchasing an additional 31 shares in the last quarter. Park Avenue Securities LLC lifted its position in Madrigal Pharmaceuticals by 6.6% during the second quarter. Park Avenue Securities LLC now owns 699 shares of the biopharmaceutical company's stock valued at $212,000 after purchasing an additional 43 shares in the last quarter. First Horizon Advisors Inc. lifted its position in Madrigal Pharmaceuticals by 38.9% during the first quarter. First Horizon Advisors Inc. now owns 157 shares of the biopharmaceutical company's stock valued at $52,000 after purchasing an additional 44 shares in the last quarter. AlphaQuest LLC lifted its position in Madrigal Pharmaceuticals by 412.5% during the second quarter. AlphaQuest LLC now owns 82 shares of the biopharmaceutical company's stock valued at $25,000 after purchasing an additional 66 shares in the last quarter. Finally, GAMMA Investing LLC lifted its position in Madrigal Pharmaceuticals by 131.4% during the first quarter. GAMMA Investing LLC now owns 118 shares of the biopharmaceutical company's stock valued at $39,000 after purchasing an additional 67 shares in the last quarter. Institutional investors own 98.50% of the company's stock.

Insiders Place Their Bets

In other Madrigal Pharmaceuticals news, Director Paul A. Friedman sold 1,400 shares of Madrigal Pharmaceuticals stock in a transaction on Friday, July 18th. The stock was sold at an average price of $350.03, for a total value of $490,042.00. Following the completion of the sale, the director owned 187,164 shares of the company's stock, valued at approximately $65,513,014.92. This trade represents a 0.74% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Rebecca Taub sold 1,000 shares of Madrigal Pharmaceuticals stock in a transaction on Friday, July 18th. The stock was sold at an average price of $350.00, for a total value of $350,000.00. Following the completion of the sale, the director directly owned 461,044 shares of the company's stock, valued at approximately $161,365,400. The trade was a 0.22% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 60,377 shares of company stock valued at $21,316,969. Corporate insiders own 21.50% of the company's stock.

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH.